IP Library Granted Patent US 10,252,088
Granted Patent B2
US 10,252,088 · App. 13/942,445 · Granted Apr 9, 2019

Topical compositions and methods of manufacturing them in specifically treated steel vessels

Inventors: Jose E. Ramirez (Trumball, CT); Austin McNamara (Villa Park, CA); Judy Hattendorf (Marina Del Rey, CA); Steve Goldner (Farmington Hills, MI)
Assignee: Obagi Cosmeceuticals LLC
A61Q19/02A61K8/347A61K8/365A61K2800/26A61K2800/87
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,252,088
App. No.
13/942,445
Granted
Apr 9, 2019
Kind
B2
Abstract

Stable hydroquinone compositions that are useful for skin care and can have a shelf life of up to three years are prepared in a tank made from a material that does not release metallic ions into the composition.

Claims (27)

1. A method comprising:

(a) passivating a stainless steel tank to chelate metallic ions therein, thereby preparing a passivated tank; and then

(b) preparing an emulsion containing hydroquinone, a preservative, a chelating agent, an emulsifier, a humectant, a pH adjuster, an antioxidant, an emollient, and a reducing agent in the passivated tank of step (a),

wherein the discoloration of the emulsion is slowed compared to the discoloration of the same emulsion that has not been prepared in the passivated tank.

2. The method of claim 1 , wherein passivating the stainless steel tank comprises contacting the stainless steel tank with a chelating acid.

3. The method of claim 2 , wherein the chelating acid is citric acid.

4. The method of claim 1 , wherein the preservative is a member selected from the group consisting of benzoic acid, benzyl alcohol, butylparaben, diazolidinyl urea, 2,3-Imidazolidinedione, isopropylparaben, isobutylparaben, methylparaben, propylparaben, sodium butylparaben, sorbic acid, and combinations thereof.

5. The method of claim 1 , wherein the chelating agent is a member selected from the group consisting of citric acid, edetate disodium, ethylenediaminetetraacetic acid, etidronic acid sodium dihydroxyethylglycinate, nitrilotriacetic acid, and combinations thereof.

6. The method of claim 1 , wherein the emulsifier is a member selected from the group consisting of cetearyl alcohol, ethoxylated fatty alcohols,PEG-1000 monocetyl ether, alkyl trimethyl ammonium bromide, polyol ester glycerol monostearate, potassium stearate, sodium lauryl sulfate, sodium cetearyl sulfate, saponins, and combinations thereof.

7. The method of claim 1 , wherein the humectant is a member selected from the group consisting of glycerin, diglycerin, triglycerin, polyglycerin, polypropylene glycol, polyethylene glycol, ethylene glycol, diethylene glycol, triethylene glycol, propylene glycol, dipropylene glycol, hexylene glycol, 1,3-butylene glycol, 1,4-butylene glycol, ethylene glycol monoalkyl ether, diethylene glycol monoalkyl ether, glucose, maltose, sucrose, lactose, xylitose, xylitol, sorbitol, mannitol, maltitol, panthenol, pentaerythritol, hyaluronic acid, and combinations thereof.

8. The method of claim 1 , wherein the pH adjuster is a member selected from the group consisting of citric acid, phosphoric acid, lactic acid, glycolic acid, and combinations thereof.

9. The method of claim 1 , wherein the antioxidant is a member selected from the group consisting of ascorbyl palmitate, 2,6 ditertiarybutyl-4-methyl phenol, butylated hydroxyanisole, tocopherol, tocopheryl acetate, propyl gallate, and combinations thereof.

10. The method of claim 1 , wherein the emollient is a member selected from the group consisting of cetyl alcohol, stearyl alcohol, liquid hydrocarbon oil, liquid natural oil, liquid fatty alcohol, liquid fatty acid, liquid fatty acid ester, liquid silicone oil, paste wax, and combinations thereof.

11. The method of claim 10 , wherein the liquid hydrocarbon oil is a member selected from the group consisting of squalane, liquid mineral oil, liquid polybutene, and combinations thereof.

12. The method of claim 10 , wherein the liquid natural oil is a member selected from the group consisting of almond oil, olive oil, sesame oil, safflower oil, avocado oil, cottonseed oil, jojoba oil, castor oil, soybean oil, palm kernel oil, coconut oil, hydrogenated vegetable oil, mink oil, egg yolk oil, and combinations thereof.

13. The method of claim 10 , wherein the liquid fatty alcohol is a member selected from the group consisting of isostearyl alcohol, lanolin alcohol, oleyl alcohol, hexadecyl alcohol, octyldodecanol alcohol, linoleyl alcohol, linolenyl alcohol, lauryl alcohol, arachidyl alcohol, and combinations thereof.

14. The method of claim 10 , wherein the liquid fatty acid is a member selected from the group consisting of caprylic acid, isostearic acid, linoleic acid, ricinoleic acid, oleic acid, and combinations thereof.

15. The method of claim 10 , wherein the liquid fatty acid ester is a member selected from the group consisting of cetyl octanoate, glyceryl trioctanoate, isopropyl linoleate, isopropyl myristate, isopropyl oleate, ethyllaurate, ethyl linoleate, octyl dodecyl myristate, octyl palmitate, octyl isopelargonate, octyl dodecyllactate, isotridecyl isononanoate, oleyl oleate, isostearyl myristate, neopentyl glycol dioctanoate, and di(capryl/capric acid) propylene glycol, and combinations thereof.

16. The method of claim 1 , wherein the reducing agent is a member selected from the group consisting of ascorbic acid, propyl gallate, sodium metabisulfite, and combination thereof.

17. The method of claim 1 , wherein the emulsion comprises a viscosity of from about 1,000 to about 50,000 centipoise.

18. The method of claim 1 , further comprising adding a sunscreen.

19. The method of claim 1 , wherein the emulsion is a lotion.

20. The method of claim 1 , wherein the emulsion maintains an acceptable color for three years.

21. The method of claim 20 , wherein the acceptable color is a color lighter than brown.

22. A method for preparing a topical hydroquinone composition, the method comprising:

preparing an emulsion containing hydroquinone, a preservative, a chelating agent, an emulsifier, a humectant, a pH adjuster, an antioxidant, an emollient and a reducing agent in a passivated stainless steel tank, wherein the stainless steel tank is passivated prior to preparing the emulsion in the stainless steel tank;

wherein the discoloration of the emulsion is slowed compared to the discoloration of the same emulsion that has been prepared in a non-passivated tank.

Assignments (16)
RELEASE OF SECURITY INTEREST Recorded Nov 17, 2025
From: TCW ASSET MANAGEMENT COMPANY LLC, AS ADMINISTRATIVE AGENT
To: OBAGI COSMECEUTICALS LLC
Reel/Frame 072928/0385 →
PATENT SECURITY AGREEMENT Recorded Nov 17, 2025
From: OBAGI COSMECEUTICALS LLC
To: LSSF II OFFSHORE INVESTMENTS, LP, AS ADMINISTRATIVE AGENT
Reel/Frame 073625/0459 →
RELEASE OF SECURITY INTEREST Recorded Apr 8, 2025
From: BARCLAYS BANK PLC, AS COLLATERAL AGENT
To: SOLTA MEDICAL, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH IRELAND LIMITED (F/K/A/ VALEANT PHARMACEUTICALS IRELAND LIMITED); SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD; SANTARUS, INC.; MEDICIS PHARMACEUTICAL CORPORATION; HUMAX PHARMACEUTICAL S.A.; SOLTA MEDICAL IRELAND LIMITED; BAUSCH & LOMB MEXICO, S.A. DE C.V.; BAUSCH+LOMB OPS B.V.; BAUSCH HEALTH AMERICAS, INC.; BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH HOLDCO LIMITED; BAUSCH HEALTH MAGYARORSZAG KFT (A/K/A BAUSCH HEALTH HUNGARY LLC); BAUSCH HEALTH POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA (F/K/A VALEANT PHARMA POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA); BAUSCH HEALTH US, LLC; BAUSCH HEALTH, CANADA INC. / SANTE BAUSCH, CANADA INC.; ICN POLFA RZESZOW SPOLKA AKCYJNA (A/K/A ICN POLFA RZESZOW S.A.); ORAPHARMA, INC.; PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA SPOLKA AKCYJNA (A/K/A PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA S.A.); SOLTA MEDICAL DUTCH HOLDINGS B.V.; V-BAC HOLDING CORP.; VRX HOLDCO LLC; 1261229 B.C. LTD.; 1530065 B.C. LTD.
Reel/Frame 070778/0199 →
RELEASE OF SECURITY INTEREST Recorded Mar 21, 2025
From: JPMORGAN CHASE BANK, N.A.
To: OBAGI COSMECEUTICALS LLC
Reel/Frame 070592/0979 →
SECURITY INTEREST Recorded Mar 18, 2025
From: OBAGI COSMECEUTICALS LLC
To: TCW ASSET MANAGEMENT COMPANY LLC, AS ADMINISTRATIVE AGENT
Reel/Frame 070546/0595 →
SECURITY INTEREST Recorded Aug 1, 2022
From: OBAGI COSMECEUTICALS LLC
To: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 060690/0148 →
RELEASE OF SECURITY INTEREST Recorded Jul 29, 2022
From: TCW ASSET MANAGEMENT COMPANY LLC
To: OBAGI COSMECEUTICALS LLC
Reel/Frame 060668/0771 →
RELEASE OF SECURITY INTEREST Recorded Mar 19, 2021
From: WELLS FARGO BANK, NATIONAL ASSOCIATION
To: OBAGI COSMECEUTICALS LLC
Reel/Frame 055652/0735 →
SECURITY INTEREST Recorded Mar 16, 2021
From: OBAGI COSMECEUTICALS LLC
To: TCW ASSET MANAGEMENT COMPANY LLC, AS COLLATERAL AGENT
Reel/Frame 055613/0083 →
NOTICE OF GRANT OF SECURITY INTEREST IN PATENTS Recorded Dec 13, 2018
From: OBAGI COSMECEUTICALS LLC
To: WELLS FARGO BANK, NATIONAL ASSOCIATION, AS ADMINISTRATIVE AGENT
Reel/Frame 047873/0114 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 11, 2017
From: OMP, INC.
To: OBAGI COSMECEUTICALS LLC
Reel/Frame 044829/0244 →
RELEASE OF SECURITY INTEREST IN SPECIFIED PATENTS Recorded Nov 14, 2017
From: BANK OF NEW YORK MELLON
To: OMP, INC.
Reel/Frame 044765/0176 →
RELEASE OF SECURITY INTEREST IN SPECIFIED PATENTS Recorded Nov 14, 2017
From: BARCLAYS BANK PLC
To: OMP, INC.
Reel/Frame 044439/0790 →
SECURITY INTEREST Recorded Jul 19, 2017
From: OMP, INC.
To: THE BANK OF NEW YORK MELLON
Reel/Frame 043041/0751 →
SECURITY INTEREST Recorded Jul 18, 2016
From: ATON PHARMA, INC.; BAUSCH & LOMB INCORPORATED; BAUSH & LOMB PHARMA HOLDINGS CORP.; DENDREON PHARMACEUTICALS, INC.; DOW PHARMACEUTICAL SCIENCES, INC.; MEDICIS PHARMACEUTICAL CORPORATION; OBAGI MEDICAL PRODUCTS, INC.; OMP, INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD; SANTARUS, INC.; SOLTA MEDICAL, INC.; VALEANT CANADA LP, BY ITS GENERAL PARTNER VALEANT CANADA GP LIMITED; VALEANT PHARMACEUTICALS INTERNATIONAL, INC.; VALEANT HOLDINGS IRELAND (AS SUCCESSOR TO VALEANT INTERNATIONAL BERMUDA); VALEANT PHARMACEUTICALS NORTH AMERICA LLC; VALEANT PHARMACEUTICALS IRELAND
To: BARCLAYS BANK PLC
Reel/Frame 039380/0385 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 3, 2015
From: RAMIREZ, JOSE E.; MCNAMARA, AUSTIN; HATTENDORF, JUDY; GOLDNER, STEVE
To: OMP, INC.
Reel/Frame 034875/0869 →
Continuity (3)
Continuation 11291453 · Dec 1, 2005
Provisional Application 60632438 · Dec 2, 2004
Related Publication 20140161746A1 · Jun 12, 2014